Primary source: Cancellation of Notified Cosmetic Products
Product registration has been cancelled for several products found to contain scheduled poisons, effective August 5, 2026.
The presence of undeclared scheduled poisons poses serious health risks to consumers. Rapid regulatory actions are crucial to ensure public safety and compliance with drug regulations.
Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.
Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.
The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia has announced the cancellation of the registration of specific complementary and alternative products following the discovery of undeclared scheduled poisons, including diphenhydramine and glibenclamide, in these products. Consumers are urged to stop using these products and consult healthcare professionals if they experience any adverse effects.
What changed: Product registration has been cancelled for several products found to contain scheduled poisons, effective August 5, 2026.
Why it matters: The presence of undeclared scheduled poisons poses serious health risks to consumers. Rapid regulatory actions are crucial to ensure public safety and compliance with drug regulations.
Practical implication: Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
